Jaguar Health, Inc. (JAGX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. ( JAGX ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Lisa Conte - Founder, CEO, President & Director Carol Lizak - Chief Financial Officer Presentation Operator Greetings, and welcome to the Jaguar Health's Investor Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Jaguar Health, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LC Louise Chen Scotiabank | -0.02 | $12,321.04 | $0.04 | $12,321 | 100% |
Jaguar Health, Inc. (JAGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jaguar Health, Inc. ever had a stock split?
Jaguar Health, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lisa A. Conte CEO | NASDAQ (CM) Exchange | 47010C862 CUSIP |
| US Country | 49 Employees | 7 Jun 2019 Last Dividend | 30 Apr 2026 Last Split | 13 May 2015 IPO Date |
Overview
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing innovative prescription medicines aimed at treating gastrointestinal distress, including chronic and debilitating diarrhea, in both humans and animals. Operating through two key segments—Human Health and Animal Health—the company seeks to address vital medical needs in underserved areas. Founded in 2013, Jaguar Health, Inc. has its headquarters in San Francisco, California, underlining its strategic positioning within a hub of biotechnological innovation and advancement.
Products and Services
- Mytesi:
A flagship product of Jaguar Health, Inc., Mytesi is a non-opioid, plant-based prescription medicine approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS who are on antiretroviral therapy. It represents a significant advancement in addressing the gastrointestinal side effects associated with long-term HIV treatment.
- Crofelemer:
Crofelemer is currently in a Phase 3 clinical trial phase and showcases Jaguar Health's commitment to expanding its gastrointestinal product portfolio. It is being developed for various indications, such as the prophylaxis of diarrhea in adult cancer patients undergoing specific treatments, and for rare or orphan diseases like Short bowel syndrome with intestinal failure, congenital diarrheal disorders, inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome, and idiopathic or functional diarrhea. This broad application underlines the versatility and potential of Crofelemer in addressing diverse gastrointestinal challenges.
- NP-300:
NP-300 represents Jaguar's effort in developing a second-generation anti-secretory antidiarrheal drug. Aimed at providing symptomatic relief and treatment for moderate-to-severe diarrhea, NP-300 is a testament to the company's ongoing research and development activities to produce innovative gastrointestinal solutions.
- Canalevia:
A unique oral, plant-based drug candidate designed specifically for the animal health segment. Canalevia is currently being developed to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea. This reflects Jaguar Health's commitment to addressing the health needs of animals, recognizing the impact of such conditions on their well-being and the need for effective, non-opioid treatments.
